Free Trial

Beximco Pharmaceuticals (LON:BXP) Stock Price Up 15.4% - Here's What Happened

Beximco Pharmaceuticals logo with Medical background

Key Points

  • Beximco Pharmaceuticals stock surged by 15.4% during trading on Wednesday, reaching a last traded price of GBX 45 ($0.60).
  • The stock's trading volume increased significantly, with 183,946 shares changing hands, a 252% rise compared to its average session volume.
  • As of the latest report, Beximco Pharmaceuticals has a market capitalization of £30.30 billion and a P/E ratio of 4.77.
  • Looking to Export and Analyze Beximco Pharmaceuticals Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Shares of Beximco Pharmaceuticals Limited (LON:BXP - Get Free Report) shot up 15.4% on Wednesday . The company traded as high as GBX 45 ($0.61) and last traded at GBX 45 ($0.61). 183,946 shares traded hands during trading, an increase of 252% from the average session volume of 52,207 shares. The stock had previously closed at GBX 39 ($0.52).

Beximco Pharmaceuticals Stock Up 3.4%

The firm has a 50-day moving average of GBX 38.46 and a two-hundred day moving average of GBX 38.01. The stock has a market capitalization of £30.68 billion, a price-to-earnings ratio of 4.83 and a beta of 0.61. The company has a quick ratio of 0.37, a current ratio of 2.13 and a debt-to-equity ratio of 12.47.

About Beximco Pharmaceuticals

(Get Free Report)

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.

Further Reading

Should You Invest $1,000 in Beximco Pharmaceuticals Right Now?

Before you consider Beximco Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beximco Pharmaceuticals wasn't on the list.

While Beximco Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines